[{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tang-Min Lin","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Entecavir","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Transgene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"||FCU1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Sutro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"STRO-002","moa":"Folate receptor alpha (FOLR1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Sutro Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Sutro Biopharma"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tianjin Tasly Group","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Infusion","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"9","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Sanhuangjingshimingwan","moa":"Immune","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Susu Xiaoer Zhike","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Susu Xiaoer Zhike","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXT3003","moa":"PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"5LGr","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Antiwei","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cerebralcare","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"11","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Changkang","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Changkang","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Danshen","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Danshen Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Dantonic","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Natural Immune Systems Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Deepure","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Natural Immune Systems Inc","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Natural Immune Systems Inc"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Ginsenoside H","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Jia Shen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Jia Shen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Jiashen","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jitongning","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Jitongning","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jiuweihuaban","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JS1-1-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS1-1-01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Lianxiaxiaopi","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Qingzhu","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"11","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Qishenyiqi","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T601","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Parexel"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"T92","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tsupport","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Xiang Ju Ru Pi Ning","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Xiang Ju Ru Pi Ning","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Huhuanglianzonggan","moa":"Unknown","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Sanhuang Jingshiming","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"B2278","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Tianjin Tasly Group
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
